BR112015018255A2 - Usos de vetores que compreendem sequência de ácido nucléico de um gene para a preparação de medicamentos para o tratamento e a prevenção de cardiomiopatia - Google Patents
Usos de vetores que compreendem sequência de ácido nucléico de um gene para a preparação de medicamentos para o tratamento e a prevenção de cardiomiopatiaInfo
- Publication number
- BR112015018255A2 BR112015018255A2 BR112015018255A BR112015018255A BR112015018255A2 BR 112015018255 A2 BR112015018255 A2 BR 112015018255A2 BR 112015018255 A BR112015018255 A BR 112015018255A BR 112015018255 A BR112015018255 A BR 112015018255A BR 112015018255 A2 BR112015018255 A2 BR 112015018255A2
- Authority
- BR
- Brazil
- Prior art keywords
- cardiomyopathy
- gene
- acid sequence
- vectors
- drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
- C12Y116/03—Oxidoreductases oxidizing metal ions (1.16) with oxygen as acceptor (1.16.3)
- C12Y116/03001—Ferroxidase (1.16.3.1), i.e. ceruloplasmin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
USOS DE VETORES QUE COMPREENDEM SEQUÊNCIA DE ÁCIDO NUCLÉICO DE UM GENE PARA A PREPARAÇÃO DE MEDICAMENTOS PARA O TRATAMENTO E A PREVENÇÃO DE CARDIOMIOPATIA. A presente invenção diz respeito a um método para prevenir ou tratar cardiomiopatia devido à insuficiência de energia em um indivíduo em necessidade do mesmo, compreendendo administrar ao dito indivíduo uma quantidade terapeuticamente eficaz de um vetor que compreende uma se-quência de ácido nucléico de um gene que pode restaurar a insuficiência de energia. Mais parti-cularmente, a invenção diz respeito a um método para prevenir ou tratar uma cardiomiopatia associada com a ataxia de Friedreich em um indivíduo em necessidade do mesmo, compreen-dendo administrar ao dito indivíduo uma quantidade terapeuticamente eficaz de um vetor que compreende um ácido nucléico que codifica a frataxina (FXN).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/756,651 US9066966B2 (en) | 2013-02-01 | 2013-02-01 | Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia |
PCT/EP2014/051966 WO2014118346A1 (en) | 2013-02-01 | 2014-01-31 | Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015018255A2 true BR112015018255A2 (pt) | 2017-08-22 |
Family
ID=50033540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015018255A BR112015018255A2 (pt) | 2013-02-01 | 2014-01-31 | Usos de vetores que compreendem sequência de ácido nucléico de um gene para a preparação de medicamentos para o tratamento e a prevenção de cardiomiopatia |
Country Status (10)
Country | Link |
---|---|
US (7) | US9066966B2 (pt) |
EP (2) | EP4324845A3 (pt) |
AU (5) | AU2014211315A1 (pt) |
BR (1) | BR112015018255A2 (pt) |
CA (1) | CA2900135A1 (pt) |
EA (1) | EA201500802A1 (pt) |
IL (2) | IL240311A0 (pt) |
MX (2) | MX2015009963A (pt) |
WO (1) | WO2014118346A1 (pt) |
ZA (2) | ZA201506093B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9066966B2 (en) * | 2013-02-01 | 2015-06-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia |
WO2016073693A2 (en) | 2014-11-05 | 2016-05-12 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
SG11201703419UA (en) * | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
AU2016206478A1 (en) * | 2015-01-16 | 2017-06-15 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
EP3273999A1 (en) | 2015-03-23 | 2018-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with friedreich ataxia |
US10617770B2 (en) | 2015-04-24 | 2020-04-14 | University Of Florida Research Foundation, Incorporated | AAV vector for treatment of Friedreich's ataxia |
EP3370778A1 (en) * | 2015-11-05 | 2018-09-12 | Bamboo Therapeutics, Inc. | Modified friedreich ataxia genes and vectors for gene therapy |
CN116059245A (zh) * | 2016-03-23 | 2023-05-05 | 加利福尼亚大学董事会 | 治疗线粒体障碍的方法 |
CA3019342A1 (en) | 2016-03-30 | 2017-10-05 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating frataxin expression |
KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
AU2017301819A1 (en) * | 2016-07-26 | 2019-02-07 | Cornell University | Gene therapy for the treatment of aldehyde dehydrogenase deficiency |
US11116852B2 (en) | 2016-11-09 | 2021-09-14 | Precigen, Inc. | Frataxin expression constructs |
US11759533B2 (en) | 2017-03-29 | 2023-09-19 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating gene expression |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
JP7128491B2 (ja) * | 2017-10-17 | 2022-08-31 | フンダシオ インスティテュート ディンベスティガシオ エン シエンシエス デ ラ サリュ ジャーマンス トライアス アイ プジョル | フリードライヒ運動失調症の治療用のベクター |
EP3774854A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
SG11202012044QA (en) * | 2018-06-29 | 2021-01-28 | Wuhan Neurophth Biological Tech Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
TW202102525A (zh) | 2019-03-21 | 2021-01-16 | 美商史崔德生物公司 | 重組腺相關病毒載體 |
MX2022004352A (es) | 2019-10-17 | 2022-07-19 | Stridebio Inc | Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c. |
WO2023150563A1 (en) * | 2022-02-01 | 2023-08-10 | Cornell University | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US941A (en) | 1838-09-22 | Machine for sawing shingles and staves | ||
US5139A (en) | 1847-06-05 | Cajsfkles | ||
US414A (en) | 1837-09-28 | Moetise-latch foe | ||
US5173A (en) | 1847-06-26 | Machinery for | ||
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
WO1994019478A1 (en) | 1993-02-22 | 1994-09-01 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
DE69925134T2 (de) * | 1998-09-11 | 2006-01-19 | The Regents Of The University Of California, La Jolla | Rekombinante adenovirus für gewebespezifische genexpression ins herz |
JP4520569B2 (ja) * | 2000-02-18 | 2010-08-04 | 照彦 豊岡 | 拡張型心筋症の遺伝子治療剤 |
EP2750686B1 (en) * | 2011-06-17 | 2017-06-14 | Shire Human Genetic Therapies, Inc. | Polypeptide comprising frataxin and a c-terminal mitochondria penetrating peptide for use in the treatment of friedreich's ataxia |
US9066966B2 (en) | 2013-02-01 | 2015-06-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia |
US10337072B2 (en) * | 2015-01-08 | 2019-07-02 | The Board Of Trustees Of The University Of Illinois | Copy number detection and methods |
EP3273999A1 (en) * | 2015-03-23 | 2018-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with friedreich ataxia |
-
2013
- 2013-02-01 US US13/756,651 patent/US9066966B2/en active Active
-
2014
- 2014-01-31 EP EP23201456.3A patent/EP4324845A3/en active Pending
- 2014-01-31 WO PCT/EP2014/051966 patent/WO2014118346A1/en active Application Filing
- 2014-01-31 EP EP14702565.4A patent/EP2950824A1/en not_active Ceased
- 2014-01-31 BR BR112015018255A patent/BR112015018255A2/pt not_active Application Discontinuation
- 2014-01-31 MX MX2015009963A patent/MX2015009963A/es unknown
- 2014-01-31 EA EA201500802A patent/EA201500802A1/ru unknown
- 2014-01-31 CA CA2900135A patent/CA2900135A1/en active Pending
- 2014-01-31 US US14/764,065 patent/US20160024526A1/en not_active Abandoned
- 2014-01-31 AU AU2014211315A patent/AU2014211315A1/en not_active Abandoned
-
2015
- 2015-05-21 US US14/718,696 patent/US10337027B2/en active Active
- 2015-07-31 MX MX2021000533A patent/MX2021000533A/es unknown
- 2015-08-02 IL IL240311A patent/IL240311A0/en unknown
- 2015-08-21 ZA ZA2015/06093A patent/ZA201506093B/en unknown
-
2017
- 2017-05-02 ZA ZA2017/03041A patent/ZA201703041B/en unknown
-
2018
- 2018-03-09 US US15/916,907 patent/US20180334687A1/en not_active Abandoned
- 2018-04-20 AU AU2018202783A patent/AU2018202783A1/en not_active Abandoned
-
2019
- 2019-05-14 US US16/411,997 patent/US20200157564A1/en not_active Abandoned
-
2020
- 2020-01-21 AU AU2020200408A patent/AU2020200408A1/en not_active Abandoned
- 2020-11-24 US US17/103,783 patent/US20210340565A1/en active Pending
-
2021
- 2021-04-05 US US17/222,500 patent/US20220090128A1/en not_active Abandoned
- 2021-12-09 AU AU2021282480A patent/AU2021282480A1/en not_active Abandoned
- 2021-12-15 IL IL289016A patent/IL289016A/en unknown
-
2024
- 2024-02-19 AU AU2024201048A patent/AU2024201048A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2900135A1 (en) | 2014-08-07 |
US20220090128A1 (en) | 2022-03-24 |
US10337027B2 (en) | 2019-07-02 |
US20160024526A1 (en) | 2016-01-28 |
US20180334687A1 (en) | 2018-11-22 |
US20200157564A1 (en) | 2020-05-21 |
AU2018202783A1 (en) | 2018-05-24 |
NZ710497A (en) | 2021-01-29 |
US20150313969A1 (en) | 2015-11-05 |
AU2020200408A1 (en) | 2020-02-13 |
ZA201703041B (en) | 2023-12-20 |
ZA201506093B (en) | 2023-12-20 |
MX2021000533A (es) | 2021-04-19 |
AU2024201048A1 (en) | 2024-03-14 |
EP4324845A3 (en) | 2024-04-17 |
IL289016A (en) | 2022-02-01 |
US9066966B2 (en) | 2015-06-30 |
US20210340565A1 (en) | 2021-11-04 |
AU2014211315A1 (en) | 2015-08-13 |
EP2950824A1 (en) | 2015-12-09 |
EA201500802A1 (ru) | 2016-01-29 |
MX2015009963A (es) | 2016-03-04 |
US20140221462A1 (en) | 2014-08-07 |
WO2014118346A1 (en) | 2014-08-07 |
AU2021282480A1 (en) | 2022-01-06 |
IL240311A0 (en) | 2015-09-24 |
EP4324845A2 (en) | 2024-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015018255A2 (pt) | Usos de vetores que compreendem sequência de ácido nucléico de um gene para a preparação de medicamentos para o tratamento e a prevenção de cardiomiopatia | |
BR112018007453A2 (pt) | genes modificados de ataxia de friedreich e vetores para a terapia gênica | |
BR112017025045A2 (pt) | plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600 | |
BR112016030462A2 (pt) | moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo | |
BR112018008783A2 (pt) | terapia-alvo de câncer | |
BR112018073861A2 (pt) | métodos de terapia de genes para doenças e condições relacionadas com a idade | |
BR112016024850A2 (pt) | composições e métodos para modulação da expressão 3 semelhante a antiopoietina | |
BR112017010662A2 (pt) | sistema de travamento mecânico para painéis de piso | |
BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
BR112017023646A2 (pt) | proteínas agonistas de receptor de cd40 de cadeia simples | |
BR112016023698A2 (pt) | cartucho de prendedores incluindo extensões que têm configurações diferentes | |
BR112018010671A8 (pt) | dispositivos e métodos de distribuição de fármaco com mudança de forma | |
BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
BR112016014986A2 (pt) | mirna tipo correspondência artificial, composição e método para suprimir expressão de um gene alvo, composição farmacêutica, método para tratar uma doença, e, ácido nucleico de fita única | |
BR112018075300A2 (pt) | métodos para tratamento do mal de alzheimer | |
BR112015030229A8 (pt) | Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado | |
BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
BR112018011838A2 (pt) | terapia gênica para distúrbios oculares | |
BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório | |
BR112018008838A2 (pt) | método para tratar, prevenir, melhorar ou administrar uma doença epiléptica | |
BR112015030355A2 (pt) | método para tratar, melhorar, inverter, proteger ou prevenir um indivíduo ou um paciente contra uma patologia, uma cardiopatia ou uma doença cardiovascular, uso, e, formulação terapêutica | |
BR112015024860A2 (pt) | vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose | |
BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
BR112018017077A2 (pt) | terapias de combinação para tratamento de atrofia muscular espinhal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |